Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascentage Pharma Group International (NASDAQ: AAPG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. Ascentage Pharma files annual reports on Form 20‑F and current reports on Form 6‑K under the Securities Exchange Act of 1934, reflecting its status as a NASDAQ‑listed biopharmaceutical company with operations in oncology and hematology.
Recent Form 6‑K filings have furnished press releases on a range of material topics, including pivotal Phase II and Phase III clinical data for Lisaftoclax and olverembatinib, regulatory clearances from the U.S. FDA and EMA for global registrational studies such as POLARIS‑1 and GLORA, publication of olverembatinib data in gastrointestinal stromal tumors, investor conference participation, interim financial results and business updates, and corporate governance items such as indemnification agreements and interest payments related to top‑up placements. These filings help investors understand the progress of Ascentage Pharma’s apoptotic pathway inhibitors, BCR‑ABL1 inhibitor programs, and protein degrader pipeline.
On Stock Titan, each new AAPG filing is captured from EDGAR and presented with AI‑generated highlights to explain the context and key points in clear language. Users can review Form 6‑K submissions related to clinical milestones, financing activities, and board decisions, and can connect these disclosures to the company’s broader oncology strategy. While Ascentage Pharma’s core SEC reporting currently emphasizes 6‑K updates, investors can also reference its Form 20‑F annual report for a more detailed discussion of risk factors, business overview, and financial statements.
In addition, this page offers quick access to historical filings so that readers can trace how Ascentage Pharma’s hematology and solid tumor programs, global partnerships, and capital markets activities have evolved over time. AI‑assisted summaries help reduce the time needed to interpret lengthy documents, highlighting items such as major clinical trial announcements, regulatory interactions, and key corporate actions disclosed in AAPG’s SEC submissions.
Ascentage Pharma Group International filed a Form 6-K to furnish its Hong Kong annual report, ESG report, AGM notice and related proxy materials to U.S. investors. The AGM will be held on May 20, 2026 at 10:00 a.m. in Suzhou, China.
Shareholders are asked to re-elect three directors, re-appoint Ernst & Young as auditor for 2026 with estimated fees of RMB5.1 million, and renew general mandates to issue shares and to repurchase up to 10% of issued shares. As at the Latest Practicable Date, issued share capital comprised 373,334,750 shares, implying a potential buyback of 37,333,475 shares under the mandate.
The company also proposes a third amended and restated memorandum and articles of association to permit hybrid and fully electronic general meetings and electronic voting, and to align with updated Hong Kong and Cayman rules on treasury shares and meeting mechanics.
Ascentage Pharma Group International files its annual Form 20-F, detailing a development-stage oncology business with significant ongoing losses and heavy R&D investment. The company reported a net loss of RMB1,243.0 million (US$177.7 million) for 2025 and accumulated losses of RMB7,013.3 million (US$1,002.9 million) as of December 31, 2025.
Revenue came mainly from product sales and collaborations, totaling RMB574.1 million (US$82.1 million) in 2025. Ascentage held RMB2,470.1 million (US$353.2 million) in cash and bank balances and had secured bank loans of RMB600.2 million (US$85.8 million), partially collateralized by buildings and right-of-use assets. Management believes existing cash and a loan facility can fund operations for at least 12 months, but not all programs through approval.
The report highlights dependence on two commercialized products in China—Olverembatinib and Lisaftoclax—ongoing global clinical trials, and substantial regulatory, financing and clinical risks. Shares are listed via American depositary shares on Nasdaq, each ADS representing four ordinary shares, with 373,322,192 ordinary shares outstanding as of April 1, 2026. Financial statements are prepared under IFRS and presented in RMB.
Ascentage Pharma Group International filed a report highlighting upcoming scientific presentations at the 2026 ASCO Annual Meeting. Six abstracts from clinical studies of three key cancer drug candidates have been accepted, including three rapid oral presentations and three poster presentations.
The work centers on Olverembatinib, Lisaftoclax and Alrizomadlin across leukemias, soft-tissue sarcomas and SDH-deficient tumors. The company also reiterates that Olverembatinib and Lisaftoclax are already approved in China for specific hematologic cancers and describes multiple ongoing global Phase III registrational trials for these agents.
Misra Veet reported acquisition or exercise transactions in this Form 4 filing.
Ascentage Pharma Group International reported a compensation-related equity grant to its Chief Financial Officer, Veet Misra. The filing shows an award of 18,584 restricted stock units (RSUs) on April 20, 2026.
Each RSU represents a contingent right to receive one Ordinary Share of the company upon vesting. According to the disclosure, these RSUs vest immediately and have no expiration date. Following this grant, the CFO directly holds 18,584 RSUs, reflecting a new equity-based incentive aligned with the company’s share performance.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an initial insider ownership report for Veet Misra, who serves as Chief Financial Officer. The available data lists Misra as the sole reporting person and shows no insider transactions or derivative positions in the excerpted information.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended insider ownership report for Chief Accounting Officer Jin Cao. The filing shows direct ownership of 5,400 Ordinary Shares, which had been inadvertently omitted previously, and 12,883 restricted stock units (RSUs).
Each RSU represents a contingent right to receive one Ordinary Share upon vesting. The RSUs vest in four equal installments on November 26 of 2026, 2027, 2028 and 2029, and do not have an expiration date.
Ascentage Pharma Group International filed a report describing its participation in the AACR 2026 Annual Meeting, where it is presenting four preclinical poster studies on combination cancer therapies. The work features three drug candidates: olverembatinib, APG-2449, and APG-5918 across hematologic malignancies and solid tumors.
The studies explore olverembatinib beyond its approved use in China for chronic myeloid leukemia, including endometrial carcinoma and mantle cell lymphoma, as well as APG-2449 in BRAF V600E-mutant tumors and APG-5918 in small-cell lung cancer. These preclinical data are intended to help guide ongoing and planned global registrational trials in multiple cancer indications.
Ascentage Pharma Group International reported the initial equity holdings of Chief Accounting Officer Jin Cao. The filing shows 12,883 restricted stock units (RSUs), each representing a contingent right to receive one Ordinary Share upon vesting.
The RSUs vest in four equal installments on November 26 of 2026, 2027, 2028 and 2029 and have no expiration date. The position is held directly and reflects equity-based compensation rather than an open-market share purchase or sale.
Ascentage Pharma Group International has changed its principal place of business in Hong Kong. Effective April 1, 2026, the address is now Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong.
The change is reported on a Form 6-K, which furnishes the related Hong Kong announcement and is signed by Chief Executive Officer Dr. Dajun Yang.
Ascentage Pharma reported unaudited 2025 results showing strong product momentum but much heavier losses. Revenue was RMB574.1 million (US$82.1 million), down from RMB980.7 million in 2024 because the prior year included RMB678.4 million of one‑off intellectual property income. Core drug sales improved: Olverembatinib revenue in China rose 80.6% to RMB435.3 million (US$62.2 million), and newly launched Lisaftoclax contributed RMB70.6 million (US$10.1 million) in its first months on the market. Investment in growth was substantial, with selling and distribution expenses up 80.4% and research and development expenses up 20.1% to RMB1,137.4 million (US$162.7 million). As a result, net loss widened sharply to RMB1,243.0 million (US$177.7 million) from RMB405.7 million. Liquidity strengthened, as cash and bank balances nearly doubled to RMB2,470.1 million (US$353.2 million), funded by a U.S. Nasdaq IPO raising US$132.5 million and a Hong Kong follow‑on offering raising US$190.1 million. Clinically, the company advanced nine registrational trials across Olverembatinib, Lisaftoclax and APG‑2449 and secured FDA and EMA clearances for additional Phase III studies, while APG‑3288, a BTK degrader, received IND clearances in the U.S. and China.